Derivatives  	Derivatives  	 NNS	O
of  	of  	 IN	O
1,4-dihydropyridines  	1,4-dihydropyridines  	 CD	O
as  	as  	 IN	O
priviledged  	priviledged  	 JJ	B-NP
structures  	structures  	 NNS	I-NP
and  	and  	 CC	O
their  	their  	 PRP$	O
pharmacological  	pharmacological  	 JJ	B-NP
potential  	potential  	 JJ	I-NP
Derivatives  	Derivatives  	 NNS	I-NP
of  	of  	 IN	O
1,4-dihydropyridine  	1,4-dihydropyridine  	 NNP	O
belong  	belong  	 VBP	O
to  	to  	 TO	O
group  	group  	 NN	O
of  	of  	 IN	O
calcium  	calcium  	 JJ	B-NP
channel  	channel  	 NN	I-NP
blockers  	blockers  	 NNS	I-NP
and  	and  	 CC	O
remain  	remain  	 VB	O
large  	large  	 JJ	O
group  	group  	 NN	O
of  	of  	 IN	O
antihypertensive  	antihypertensive  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
Particular  	Particular  	 JJ	B-NP
chemical  	chemical  	 NN	I-NP
structure  	structure  	 NN	I-NP
and  	and  	 CC	O
presence  	presence  	 NN	O
of  	of  	 IN	O
highly  	highly  	 RB	O
reactive  	reactive  	 JJ	B-NP
binding  	binding  	 JJ	I-NP
groups  	groups  	 NNS	I-NP
make  	make  	 VBP	O
1,4-dihydropyridines  	1,4-dihydropyridines  	 RB	O
privileged  	privileged  	 JJ	O
structures 	structures 	 NNS	O
,  	,  	 ,	O
which  	which  	 WDT	O
can  	can  	 MD	O
be  	be  	 VB	O
modified  	modified  	 VBN	O
and  	and  	 CC	O
change  	change  	 VB	O
their  	their  	 PRP$	O
pharmacological  	pharmacological  	 JJ	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
fact  	fact  	 NN	O
applies  	applies  	 VBZ	O
to  	to  	 TO	O
new  	new  	 JJ	O
derivatives  	derivatives  	 NNS	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
metabolites  	metabolites  	 NN	B-NP
of  	of  	 IN	O
those  	those  	 DT	O
drugs 	drugs 	 NNS	O
.  	.  	 .	O
Particularly  	Particularly  	 RB	O
interesting  	interesting  	 JJ	O
are  	are  	 VBP	O
outcomes  	outcomes  	 VBN	O
of  	of  	 IN	O
experiments  	experiments  	 NNS	O
with  	with  	 IN	O
metabolites  	metabolites  	 NN	B-NP
of  	of  	 IN	I-NP
furnidypine 	furnidypine 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
tend  	tend  	 VBP	O
to  	to  	 TO	O
cause  	cause  	 VB	O
different  	different  	 JJ	O
pharmacological  	pharmacological  	 JJ	B-NP
effect 	effect 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
have  	have  	 VB	O
different  	different  	 JJ	O
profile  	profile  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
from  	from  	 IN	O
mother  	mother  	 NN	O
drug 	drug 	 NN	O
.  	.  	 .	O
Our  	Our  	 PRP$	O
paper  	paper  	 NN	B-NP
concerns  	concerns  	 NNS	I-NP
with  	with  	 IN	O
potential  	potential  	 JJ	B-NP
new  	new  	 JJ	I-NP
possibilities  	possibilities  	 NNS	I-NP
of  	of  	 IN	O
using  	using  	 VBG	O
derivatives  	derivatives  	 NNS	O
of  	of  	 IN	O
1,4-dihydropyridines 	1,4-dihydropyridines 	 NNP	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
their  	their  	 PRP$	O
metabolites 	metabolites 	 NN	B-NP
,  	,  	 ,	O
as  	as  	 IN	O
agents  	agents  	 NNS	O
of  	of  	 IN	O
more  	more  	 RBR	O
optimised  	optimised  	 JJ	B-NP
effect 	effect 	 NN	I-NP
.  	.  	 .	O
